Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
A treatment to prevent extreme symptoms and cut hospitalisation
Demand normalisation post the second wave contributed to the steady growth
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
KIMS Hospitals' brand, has an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021
The collaboration will support Canada with direct access to rapid pandemic response capabilities
The aim is to create new genomics solutions that could combat cancer and advance market access
The company has tied up with OrbiMed as a financial partner for global reach
The profits were bolstered by the Boehringer Ingelheim MEK program income
Subscribe To Our Newsletter & Stay Updated
